{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:26:28Z","timestamp":1791588388940,"version":"4.3.4"},"reference-count":13,"publisher":"Wiley","issue":"s5","license":[{"start":{"date-parts":[[2007,12,7]],"date-time":"2007-12-07T00:00:00Z","timestamp":1196985600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Recently, three multicentre prospective international studies have been carried out to evaluate the clinical efficacy and safety of Fanhdi<jats:sup>\u00ae<\/jats:sup> [high\u2010purity, double\u2010inactivated plasma\u2010derived factor VIII\/von Willebrand factor (VWF) concentrate] in patients with von Willebrand\u2019s disease (VWD). Pharmacokinetic parameters, clinical efficacy and safety of Fanhdi<jats:sup>\u00ae<\/jats:sup> in acute bleedings episodes or invasive procedures were determined in this population.<\/jats:p><jats:p> <jats:bold>Results<\/jats:bold>. Pharmacokinetic parameters observed were similar to previous reported for other highly purified plasma\u2010derived FVIII\/VWF concentrate. The mean <jats:italic>in vivo<\/jats:italic> recovery (IU\u2003dL<jats:sup>\u22121<\/jats:sup> per IU\u2003kg<jats:sup>\u22121<\/jats:sup>) was 1.9\u2003\u00b1\u20030.6 for VWF:RCof; 2.1\u2003\u00b1\u20030.6 for VWF:Ag and 2.6\u2003\u00b1\u20030.6 for FVIII:C. The mean half\u2010life (h) was 14.4\u2003\u00b1\u200310.5 for VWF:RCof; 27.5\u2003\u00b1\u200311.0 for VWF:Ag and 33.4\u2003\u00b1\u200316.4 for FVIII:C. Therapeutic benefit of Fanhdi<jats:sup>\u00ae<\/jats:sup> in VWD patients treated during bleeding episodes was clearly demonstrated. The achievement of haemostasis was excellent or good in 100% of the cases (major or minor bleeding episodes). Also, the clinical efficacy of Fanhdi<jats:sup>\u00ae<\/jats:sup> in preventing excessive bleeding during surgery showed a very good profile. Efficacy was rated as excellent in six cases (three major\/three minor surgical procedures) and good in three cases (two major\/one minor surgical procedures). In addition, the product was well tolerated and no adverse events potentially related to the study drug were reported.<\/jats:p><jats:p> <jats:bold>Conclusions<\/jats:bold>. Fanhdi<jats:sup>\u00ae<\/jats:sup> is an effective and safe plasma\u2010derived FVIII\/VWF concentrate that can be used as an alternative to the current replacement therapy in patients with VWD to provide an adequate haemostasis during surgical procedures and treatment of bleeding episodes.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2007.01570.x","type":"journal-article","created":{"date-parts":[[2010,9,15]],"date-time":"2010-09-15T13:04:50Z","timestamp":1284555890000},"page":"25-32","source":"Crossref","is-referenced-by-count":26,"title":["Fanhdi<sup>\u00ae<\/sup>, efficacy and safety in von Willebrand\u2019s disease: prospective international study results"],"prefix":"10.1111","volume":"13","author":[{"given":"I. F.","family":"BELLO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. J.","family":"YUSTE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Q.","family":"MOLINA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.H.","family":"NAVARRO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,12,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.0050s2028.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.395"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1997.tb00172.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.1997.242.s740.129"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.48.1.525"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00147.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330370053031"},{"key":"e_1_2_6_9_2","first-page":"93","article-title":"Concentrado de FVIII de alta pureza con doble inactivaci\u00f3n viral: estudio de farmacocin\u00e9tica en pacientes con enfermedad de Von Willebrand [High, purity human factor VIII concentrate with two viral inactivation steps: pharmacokinetic study in patients with Von Willebrand disease]","volume":"43","author":"Canales MA","year":"1998","journal-title":"Sangre"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x"},{"key":"e_1_2_6_11_2","first-page":"796","article-title":"Use of a plasma\u2010derived high\u2010purity and double viral inactivated factor VIII concentrate in the treatment of von Willebrand disease","volume":"82","author":"Villar A","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00816.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649942"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.0050s2064.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2007.01570.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2007.01570.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:18:38Z","timestamp":1695712718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2007.01570.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":13,"journal-issue":{"issue":"s5","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1365-2516.2007.01570.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01570.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}